Characterization of persistent and recurrent Cushing's disease

Pituitary

Volumn 17, Issue 4, 2014, Pages 381-391

  Sundaram, Nina K ^a   Carluccio, Alessia ^a   Geer, Eliza B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cushing's disease; Persistence; Pituitary; Recurrence; Remission; Treatment

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; DESMOPRESSIN; DEXAMETHASONE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ANTAGONIST; HEMOGLOBIN A1C; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MIDNIGHT SALIVARY FREE CORTISOL; MIFEPRISTONE; MINERALOCORTICOID; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 5; STEROID 11BETA MONOOXYGENASE; UNCLASSIFIED DRUG;

ACTH SECRETING ADENOMA; ACTH SECRETING CELL; ADRENAL HYPERTROPHY; ADRENAL NECROSIS; ADRENALECTOMY; ANXIETY DISORDER; ARTICLE; BINDING AFFINITY; BONE DENSITY; CANCER RADIOTHERAPY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CIRCADIAN RHYTHM; CLINICAL DECISION MAKING; COMORBIDITY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CRANIAL NERVE PARALYSIS; CUSHING DISEASE; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BINDING; DRUG DOSE COMPARISON; ENDOMETRIAL THICKNESS; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GLUCOSE INTOLERANCE; HORMONE INHIBITION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYDROCORTISONE SALIVA LEVEL; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHY; HYPOKALEMIA; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOHISTOCHEMISTRY; INSOMNIA; INTERMETHOD COMPARISON; LANGUAGE DISABILITY; LAPAROSCOPIC SURGERY; LOW DRUG DOSE; MANIA; MEMORY DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; NELSON SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OSTEOPOROSIS; PERSISTENT DISEASE; PHOTON THERAPY; PHYSICAL DISEASE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HYPOCORTISOLISM; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION NECROSIS; RECURRENT DISEASE; REMISSION; REOPERATION; SALIVA LEVEL; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; STEROIDOGENESIS; SURGICAL RISK; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT CONTRAINDICATION; VISUAL FIELD DEFECT; WEIGHT GAIN; DRUG EFFECTS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PATHOLOGY; PATHOPHYSIOLOGY; PITUITARY ACTH HYPERSECRETION;

DEXAMETHASONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY ACTH HYPERSECRETION;

EID: 84904100927     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0511-3     Document Type: Article

References (94)

1. Ambrosi B, Faglia G, the Multicenter Pituitary umor Study Group, Lombardia Region (1991) Epidemiology of pituitary tumors. In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds) Pituitary adenomas: new trends in basic and clinical research. Excerpta Medica, Amsterdam, pp 159-168
2. Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 40(4):479-484 (Pubitemid 24194645)
3. Plotz CM, Knowlton AI, Ragan C (1952) The natural history of Cushing's syndrome. Am J Med 13(5):597-614
4. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stella GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454-2462 (Pubitemid 352008503)
5. Boscaro M, Barzon L, Fallo F, Sonino N (2001) Cushing's syndrome. Lancet 357(9258):783-791 (Pubitemid 32217692)
6. Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19(5):647-672 (Pubitemid 28467716)
7. Findling JW, Raff H (2006) Cushing's Syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 91(10):3746-3753 (Pubitemid 44536836)
8. Starkman MN, Schteingart DE (1981) Neuropsychiatric manifestations of patients with Cushing's syndrome. Relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med 141(2):215-219 (Pubitemid 11130261)
9. Dorn LD, Burgess ES, Dubbert B, Simpson SE, Friedman T, Kling M, Gold PW, Chrousos GP (1995) Psychopathology in patients with endogenous Cushing's syndrome: "atypical" or melancholic features. Clin Endocrinol (Oxf) 43(4):433-442
10. Chee GH, Mathias DB, James RA, Kendall-Taylor P (2001) Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome? Clin Endocrinol (Oxf) 54(5):617-626 (Pubitemid 34208905)
11. Estrada J, Garcia-Uria J, Lamas C, Alfaro J, Lucas T, Diez S, Salto L, Barcelo B (2001) The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 86(12):5695-5699 (Pubitemid 33152610)
12. Pereira AM, van Aken MO, van Dulken H, Schutte PJ, Biermasz NR, Smit JW, Roelfsema F, Romijn JA (2003) Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab 88(12):5858-5864 (Pubitemid 38033063)
13. Carrasco CA, Coste J, Guignat L, Groussin L, Duque MA, Gaillard S, Bertagna X, Betherat J (2008) Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing's disease. J Clin Endocrinol Metab 93(12):4728-4734
14. Valero R, Vallette-Kasic S, Conte-Devolx B, Jaquet P, Brue T (2004) The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing's disease. Eur J Endocrinol 151(6):727-733 (Pubitemid 40090012)
15. Salem V, Dhillo WS, Meeran K, Donaldson M, Martin NM (2010) Dexamethasone-suppressed corticotrophin-releasing hormone-stimulation test does not reliably diagnose or predict recurrence of Cushing disease. Clin Chem 56(6):1031-1034
16. Schrell U, Fahlbusch R, Buchfelder M, Riedl S, Stalla GK, Muller OA (1987) Corticotropin-releasing hormone stimulation test before and after transsphenoidal selective microadenomectomy in 30 patients with Cushing's disease. J Clin Endocrinol Metab 64(6):1150-1159 (Pubitemid 17074771)
17. Shimon I, Ram Z, Cohen ZR, Hadani M (2002) Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51(1):57-61 discussion 61-2
18. Hammer GD, Tyrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB (2004) Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 89(12):6348-6357 (Pubitemid 39628458)
19. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B (2005) Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 63(5):549-559 (Pubitemid 41626751)
20. Chen JC, Amar AP, Choi S, Singer P, Couldwell WT, Weiss MH (2003) Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg 98(5):967-973 (Pubitemid 36460886)
21. Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang C, Swerdloff RS, Kelly DF (2006) Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 91(1):7-13 (Pubitemid 43069107)
22. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF (2002) Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 56(4):541-551 (Pubitemid 34429630)
23. Yap LB, Turner HE, Adams CB, Wass JA (2002) Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf) 56(1):25-31 (Pubitemid 34107318)
24. McCance DR, Besser M, Atkinson AB (1996) Assessment of cure after transsphenoidal surgery for Cushing's disease. Clin Endocrinol (Oxf) 44(1):1-6 (Pubitemid 26025679)
25. Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Savage MO, Afshar F, Besser GM (1993) Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf) 38(1):73-78 (Pubitemid 23030276)
26. Pieters GF, Hermus AR, Meijer E, Smals AG, Kloppenborg PW (1989) Predictive factors for initial cure and relapse rate after pituitary surgery for Cushing's disease. J Clin Endocrinol Metab 69(6):1122-1126 (Pubitemid 20010036)
27. Locatelli M, Vance ML, Laws ER (2005) Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 90(9):5478-5482 (Pubitemid 41262319)
28. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws ER (2008) Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93(2):358-362 (Pubitemid 351246675)
29. Alexandraki KI, Kaltsas GA, Isidori AM, Storr HL, Afshar F, Sabin I, Akker SA, Chew SL, Drake WM, Monson JP, Besser GM, Grossman AB (2013) Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. Eur J Endocrinol 168(4):639-648
30. Hofmann BM, Hlavac M, Martinez R, Buchfelder M, Muller OA, Fahlbusch R (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108(1):9-18
31. Toms GC, McCarthy MI, Nieven MJ, Orteu CH, King TT, Monson JP (1993) Predicting relapse after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 76(2):291-294 (Pubitemid 23073044)
32. Valassi E, Biller BM, Swearingen B, Pecori Giraldi F, Losa M, Mortini P, Hayden D, Cavagnini F, Klibanski A (2010) Delayed remission after transsphenoidal surgery in patients with Cushing's disease. J Clin Endocrinol Metab 95(2):601-610
33. Bochicchio D, Losa M, Buchfelder M (1995) Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 80(11):3114-3120
34. Newell-Price J, Trainer P, Besser M, Grossman A (1998) The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19(5):647-672 (Pubitemid 28467716)
35. Kidambi S, Raff H, Findling JW (2007) Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol 157(6):725-731
36. Raff H, Raff JL, Findling JW (1998) Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab 83(8):2681-2686 (Pubitemid 28493760)
37. Putignano P, Toja P, Dubini A, Pecori Giraldi F, Corsello SM, Cavagnini F (2003) Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. J Clin Endocrinol Metab 88(9):4153-4157 (Pubitemid 37153715)
38. Hofmann BM, Hlavac M, Kreutzer J, Grabenbauer G, Fahlbusch R (2006) Surgical treatment of recurrent Cushing's disease. Neurosurgery 58(6):1108-1118 discussion 1108-1118
39. Dickerman RD, Oldfield EH (2002) Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. J Neurosurg 97(6):1343-1349 (Pubitemid 35424289)
40. Nakane T, Kuwayama A, Watanabe M, Takahashi T, Kato T, Ichihara K, Kageyama N (1987) Long term results of transsphenoidal adenomectomy in patients with Cushing's disease. Neurosurgery 21(2):218-222 (Pubitemid 17131122)
41. Benveniste RJ et al (2005) Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 102(6):1004-1012 (Pubitemid 43193968)
42. Hofmann BM, Fahlbusch R (2006) Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Front Horm Res 34:158-184 (Pubitemid 43265658)
43. Knappe UJ, Lüdecke DK (1996) Persistent and recurrent hypercortisolism after transsphenoidal surgery for Cushing's disease. Acta Neurochir Suppl 65:31-34 (Pubitemid 126446155)
44. Friedman RB, Oldfield RB, Nieman LK, Chrousos GP, Doppman JL, Cutler GB, Loriaux DL (1989) Repeat transsphenoidal surgery for Cushing's disease. J Neurosurg 71(4):520-527 (Pubitemid 19244267)
45. Knappe UJ, Lüdecke DK (1996) Transnasal microsurgery in children and adolescents with Cushing's disease. Neurosurgery 39(3):484-492 discussion 492-493
46. Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER (2008) Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery 63(2):266-270 discussion 270-271
47. Estrada J, Boronat M, Mielgo M, Magallón R, Millan I, Díez S, Lucas T, Barceló B (1997) The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 336(3):172-177 (Pubitemid 27034962)
48. McLaughlin N, Kassam AB, Prevedello DM, Kelly DF (2011) Management of Cushing's disease after failed surgery - a review. Can J Neurol Sci 38(1):12-21
49. Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER (2000) Radiosurgery for Cushing's disease after failed transsphenoidal surgery. J Neurosurg 93(5):738-742 (Pubitemid 32803394)
50. Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML (2007) Gamma Knife surgery for Cushing's disease. J Neurosurg 106(6):980-987 (Pubitemid 46871110)
51. Castinetti F, Nagai M, Dufour H, Kuhn JM, Morange I, Jaquet P, Conte-Devolx B, Regis J, Brue T (2007) Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur J Endocrinol 156(1):91-98 (Pubitemid 46553907)
52. Aghi MK, Petit J, Chapman P, Loeffler J, Klibanski A, Biller BK, Swearingen B (2008) Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. Clin Neurosurg 55:141-144
53. Petit JH, Biller BK, Yock TI, Swearingen B, Coen JJ, Chapman P, Ancukiewicz M, Bussiere M, Klibanski A, Loeffler JS (2008) Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 93(2):393-399 (Pubitemid 351246676)
54. Kelly DF (2007) Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome. Neurosurg Focus 23(3):E5
55. Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML, Young WF (2008) Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clin Endocrinol (Oxf) 68(4):513-519 (Pubitemid 351388707)
56. Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL, Sheppard BC (2007) Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience. Ann Surg 245(5):790-794 (Pubitemid 46684110)
57. Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing's Disease: a reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab 92(1):172-179 (Pubitemid 46067527)
58. Brunicardi FC, Rosman PM, Lesser KL, Andersen DK (1985) Current status of adrenalectomy for Cushing's disease. Surgery 98(6):1127-1134 (Pubitemid 16104734)
59. Sonino N, Zielezney M, Fava GA, Fallo F, Boscaro M (1996) Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 81(7):2647-2652 (Pubitemid 26240292)
60. Miller JW, Crapo L (1993) The medical treatment of Cushing's syndrome. Endocr Rev 14(4):443-458 (Pubitemid 23238926)
61. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 158(1):91-99 (Pubitemid 351211045)
62. Sonino N, Boscaro M (1999) Medical therapy for Cushing's disease. Endocrinol Metab Clin North Am 28(1):211-222 (Pubitemid 29164785)
63. Sonino N, Boscaro M, Fallo F (2005) Pharmacologic management of Cushing syndrome: new targets for therapy. Treat Endocrinol 4(2):87-94 (Pubitemid 40516576)
64. Fleseriu M, Petersenn S (2012) Medical management of Cushing's disease: what is the future? Pituitary 15(3):330-341
65. Hale AC, Coates PJ, Doniach I, Howlett TA, Grossman A, Rees LH, Besser GM (1988) A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing's disease. Clin Endocrinol (Oxf) 28(2):215-223 (Pubitemid 18055759)
66. Koppeschaar HP, Croughs RJ, Thijssen JH, Schwarz F (1986) Response to neurotransmitter modulating drugs in patients with Cushing's disease. Clin Endocrinol (Oxf) 25(6):661-667 (Pubitemid 17187545)
67. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro MLDB, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SWJ (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89(5):2452-2462 (Pubitemid 38619889)
68. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SWJ, Colao A (2009) The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223-230
69. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol 163(5):709-716
70. Colao A, Petersenn S, Newell-Price J (2011) Pasireotide (SOM230) demonstrates efficacy in patients with Cushing disease: results from a large, randomized-dose, double-blind, phase III study. in ENDO 2011. Boston
71. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide B2305 Study Group (2012) A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 366(10):914-924
72. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, SEISMIC Study Investigators (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 97(6):2039-2049
73. Blevins LS, Christy JH, Khajavi M, Tindall GT (1998) Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 83(1):63-67 (Pubitemid 28498311)
74. Barbetta L, Dall'Asta C, Tomei G, Locatelli M, Giovanelli M, Ambrosi B (2001) Assessment of cure and recurrence after pituitary surgery for Cushing's disease. Acta Neurochir (Wein) 143(5):477-481 discussion 481-482
75. Rollin GA, Ferreira NP, Junges M, Gross JL, Czepielewski MA (2004) Dynamics of serum cortisol levels after transsphenoidal surgery in a cohort of patients with Cushing's disease. J Clin Endocrinol Metab 89(3):1131-1139 (Pubitemid 38368401)
76. Boggan JE, Tyrrell JB, Wilson CB (1983) Transsphenoidal microsurgical management of Cushing's disease. Report of 100 cases. J Neurosurg 59(2):195-200 (Pubitemid 13029195)
77. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F (1999) Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84(2):440-448
78. Castinetti F, Martinie M, Morange I, Dufour H, Sturm N, Passagia JG, Conte-Devolx B, Chabre O, Brue T (2009) A combined dexamethasone desmopressin test as an early marker of postsurgical recurrence in Cushing's disease. J Clin Endocrinol Metab 94(6):1897-1903
79. Valassi E, Crespo I, Santos A, Webb SM (2012) Clinical consequences of Cushing's syndrome. Pituitary 15(3):319-329
80. Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP, Nieman LK (2007) Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res 22:110-118 (Pubitemid 46032603)
81. Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J, Webb SM (2009) Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab 94(9):3365-3371
82. Krsek M, Silha JV, Jezková J, Hána V, Marek J, Weiss V, Stepán JJ, Murphy LJ (2004) Adipokine levels in Cushing's syndrome; elevated resistin levels in female patients with Cushing's syndrome. Clin Endocrinol (Oxf) 60(3):350-357 (Pubitemid 38297126)
83. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G (1999) Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 84(8):2664-2672 (Pubitemid 30641990)
84. Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJSA, Wassenaar MJ, Middelkoop HAM, Pereira AM, Romijn JA (2010) Subtle cognitive impairments in patients with long-term cure of Cushing's disease. J Clin Endocrinol Metab 95(6):2699-2714
85. Hook JN, Giordani B, Schteingart DE, Guire K, Giles J, Ryan K, Gebarski SS, Langenecker SA, Starkman MN (2007) Patterns of cognitive change over time and relationship to age following successful treatment of Cushing's disease. J Int Neuropsychol Soc 13(1):21-29 (Pubitemid 46487372)
86. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP (1997) The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82(3):912-919 (Pubitemid 27106611)
87. Tiemensma J, Biermasz NR, Middelkoop HAM, van der Mast RC, Romijn JA, Pereira AM (2010) Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease. J Clin Endocrinol Metab 95(10):E129-E141
88. van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JWA, Roelfsema F, Lamberts SWJ, Romijn JA (2005) Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab 90(6):3279-3286 (Pubitemid 41014287)
89. Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117-123 (Pubitemid 32111743)
90. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK (2006) Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 91(2):447-453 (Pubitemid 43236908)
91. Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SWJ et al (2008) Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol 158(5):623-630 (Pubitemid 351639599)
92. Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Endocrinol 154(1):109-118 (Pubitemid 43250744)
93. Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Wägner AM, Rodriguez-Espinosa J, Farrerons J, Webb SM (2009) Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. J Bone Miner Res 24(11):1841-1846
94. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB (2013) Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. J Clin Endocrinol Metab 98(3):1022-1030